{"pmid":32432162,"title":"Pharmaco-invasive Therapy for STEMI in a Patient with COVID-19: A Case Report.","text":["Pharmaco-invasive Therapy for STEMI in a Patient with COVID-19: A Case Report.","Coronavirus disease 2019 (COVID-19) is a pandemic that started in the Wuhan province of China in December 2019. It is associated with increased morbidity and mortality mainly due to severe acute respiratory syndrome 2 (SARS-Cov-2). Cardiac manifestations related to COVID-19 include demand ischemia, fulminant myocarditis, myocardial infarction and arrhythmias. In this report, we present a case of ST-segment elevation myocardial infarction (STEMI) in a 68-year-old man with COVID-19 who initially presented with chest pain and shortness of breath. Patient's STEMI was managed with pharmaco-invasive strategy with tissue plasminogen activator (t-PA). He then developed acute hypoxic respiratory failure that was managed in the intensive care unit (ICU), together with multi-organ failure from which the patient died 2 days after presentation. Although the pathophysiologic mechanisms of STEMI in COVID-19 patients has not been clearly established, we hypothesize that interrelated pathogenetic factors, that we highlight in this report, can play a role in the development of STEMI, including plaque rupture secondary to systemic inflammation, increased pro-coagulants, endothelial dysfunction, impaired fibrinolysis and impaired oxygen utilization leading to demand/supply mismatch and myocardial ischemia.","Am J Med Case Rep","Kariyanna, Pramod Theetha","Hossain, Naseem","Jayarangaiah, Apoorva","Hossain, Nimrah A","Francois, Jonathan Christopher","Marmur, Jonathan D","Salifu, Moro O","McFarlane, Samy I","32432162"],"abstract":["Coronavirus disease 2019 (COVID-19) is a pandemic that started in the Wuhan province of China in December 2019. It is associated with increased morbidity and mortality mainly due to severe acute respiratory syndrome 2 (SARS-Cov-2). Cardiac manifestations related to COVID-19 include demand ischemia, fulminant myocarditis, myocardial infarction and arrhythmias. In this report, we present a case of ST-segment elevation myocardial infarction (STEMI) in a 68-year-old man with COVID-19 who initially presented with chest pain and shortness of breath. Patient's STEMI was managed with pharmaco-invasive strategy with tissue plasminogen activator (t-PA). He then developed acute hypoxic respiratory failure that was managed in the intensive care unit (ICU), together with multi-organ failure from which the patient died 2 days after presentation. Although the pathophysiologic mechanisms of STEMI in COVID-19 patients has not been clearly established, we hypothesize that interrelated pathogenetic factors, that we highlight in this report, can play a role in the development of STEMI, including plaque rupture secondary to systemic inflammation, increased pro-coagulants, endothelial dysfunction, impaired fibrinolysis and impaired oxygen utilization leading to demand/supply mismatch and myocardial ischemia."],"journal":"Am J Med Case Rep","authors":["Kariyanna, Pramod Theetha","Hossain, Naseem","Jayarangaiah, Apoorva","Hossain, Nimrah A","Francois, Jonathan Christopher","Marmur, Jonathan D","Salifu, Moro O","McFarlane, Samy I"],"date":"2020-05-21T11:00:00Z","year":2020,"_id":"32432162","source":"PubMed","week":"202021|May 18 - May 24","keywords":["covid-19","pharmaco-invasive therapy","st-segment elevation myocardial infarction (stemi)"],"locations":["Wuhan","China","Pharmaco"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Case Report"],"weight":1,"_version_":1667342288321249280,"score":9.490897,"similar":[{"pmid":32490506,"title":"Coronavirus disease 2019 (COVID-19) and simultaneous acute anteroseptal and inferior ST-segment elevation myocardial infarction.","text":["Coronavirus disease 2019 (COVID-19) and simultaneous acute anteroseptal and inferior ST-segment elevation myocardial infarction.","Coronavirus disease 2019 (COVID-19) is a recently recognised pandemic spreading rapidly from Wuhan, Hubei, to other provinces in China and to many countries around the world. The number of COVID-19-related deaths is steadily increasing. Acute ST-segment elevation myocardial infarction (STEMI) is a disease with high morbidity and mortality rates, and primary percutaneous coronary intervention is usually recommended for the treatment. A patient with diabetes mellitus and hypertension for five years was admitted to the emergency unit with symptoms of fever, cough and dyspnoea. These symptoms were consistent with viral pneumonia and a COVID PCR test was performed, which tested positive three days later. The patient had chest pain on the eighth day of hospitalisation. On electrocardiography, simultaneous acute inferior and anterior STEMI were identified. High levels of stress and increased metabolic demand in these patients may lead to concomitant thrombosis of different coronary arteries, presenting with two different STEMIs.","Cardiovasc J Afr","Yolcu, Mustafa","Gunesdogdu, Fusun","Bektas, Metin","Bayirli, Derya Turan","Serefhanoglu, Kivanc","32490506"],"abstract":["Coronavirus disease 2019 (COVID-19) is a recently recognised pandemic spreading rapidly from Wuhan, Hubei, to other provinces in China and to many countries around the world. The number of COVID-19-related deaths is steadily increasing. Acute ST-segment elevation myocardial infarction (STEMI) is a disease with high morbidity and mortality rates, and primary percutaneous coronary intervention is usually recommended for the treatment. A patient with diabetes mellitus and hypertension for five years was admitted to the emergency unit with symptoms of fever, cough and dyspnoea. These symptoms were consistent with viral pneumonia and a COVID PCR test was performed, which tested positive three days later. The patient had chest pain on the eighth day of hospitalisation. On electrocardiography, simultaneous acute inferior and anterior STEMI were identified. High levels of stress and increased metabolic demand in these patients may lead to concomitant thrombosis of different coronary arteries, presenting with two different STEMIs."],"journal":"Cardiovasc J Afr","authors":["Yolcu, Mustafa","Gunesdogdu, Fusun","Bektas, Metin","Bayirli, Derya Turan","Serefhanoglu, Kivanc"],"date":"2020-06-04T11:00:00Z","year":2020,"_id":"32490506","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10-5830-CVJA-2020-016","keywords":["covid-19","acute anterior wall myocardial infarction","acute inferior wall myocardial infarction"],"locations":["Wuhan","Hubei","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Case Report"],"weight":1,"_version_":1668623433636773889,"score":346.9657},{"pmid":32352633,"title":"Insights for increased risk of failed fibrinolytic therapy and stent thrombosis associated with COVID-19 in ST-segment elevation myocardial infarction patients.","text":["Insights for increased risk of failed fibrinolytic therapy and stent thrombosis associated with COVID-19 in ST-segment elevation myocardial infarction patients.","Important health resources are dedicated worldwide to the management of COVID-19. This new disease, due to its large diffusion, may significantly hamper the prognosis of other pathologies, such as ST-segment elevation myocardial infarction (STEMI) because of (a) a possible direct negative impact and (b) shortage of first response medical resources and increased delays to reperfusion. We report the case of a 68-year-old man admitted for anterior STEMI and asymptomatic COVID-19. Due to extended transportation delays to a cathlab, he received intravenous fibrinolytic therapy, which failed. Reperfusion was achieved with rescue coronary angioplasty, but the patient experienced two episodes of acute stent thrombosis at 2- and 36-hr following admission and despite optimal medical therapy. He finally died because of cardiogenic shock. This raises concerns about a possible increase in platelet aggregability associated with COVID-19 leading to an increased risk of stent thrombosis, particularly in the context of STEMI. This pleads for the promotion of primary coronary angioplasty as the first-choice revascularization technique in this population and the use of new generation P2Y12 inhibitors. In addition, the use of GPIIb/IIIa inhibitors may be considered in every STEMI patient with COVID-19 to prevent the risk of acute stent thrombosis.","Catheter Cardiovasc Interv","Lacour, Thibaud","Semaan, Carl","Genet, Thibaud","Ivanes, Fabrice","32352633"],"abstract":["Important health resources are dedicated worldwide to the management of COVID-19. This new disease, due to its large diffusion, may significantly hamper the prognosis of other pathologies, such as ST-segment elevation myocardial infarction (STEMI) because of (a) a possible direct negative impact and (b) shortage of first response medical resources and increased delays to reperfusion. We report the case of a 68-year-old man admitted for anterior STEMI and asymptomatic COVID-19. Due to extended transportation delays to a cathlab, he received intravenous fibrinolytic therapy, which failed. Reperfusion was achieved with rescue coronary angioplasty, but the patient experienced two episodes of acute stent thrombosis at 2- and 36-hr following admission and despite optimal medical therapy. He finally died because of cardiogenic shock. This raises concerns about a possible increase in platelet aggregability associated with COVID-19 leading to an increased risk of stent thrombosis, particularly in the context of STEMI. This pleads for the promotion of primary coronary angioplasty as the first-choice revascularization technique in this population and the use of new generation P2Y12 inhibitors. In addition, the use of GPIIb/IIIa inhibitors may be considered in every STEMI patient with COVID-19 to prevent the risk of acute stent thrombosis."],"journal":"Catheter Cardiovasc Interv","authors":["Lacour, Thibaud","Semaan, Carl","Genet, Thibaud","Ivanes, Fabrice"],"date":"2020-05-01T11:00:00Z","year":2020,"_id":"32352633","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1002/ccd.28948","keywords":["acute myocardial infarction","antithrombotic treatment","viral infection"],"topics":["Case Report"],"weight":1,"_version_":1666138495758893056,"score":344.67484},{"pmid":32425198,"pmcid":"PMC7229476","title":"North American COVID-19 ST-segment elevation myocardial infarction (NACMI) registry: Rationale, design, and implications.","text":["North American COVID-19 ST-segment elevation myocardial infarction (NACMI) registry: Rationale, design, and implications.","Background: The novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), that causes coronavirus disease 2019 (COVID-19), has resulted in a global pandemic. Patients with cardiovascular risk factors or established cardiovascular disease are more likely to experience severe or critical COVID-19 illness and myocardial injury is a key extra-pulmonary manifestation. These patients frequently present with ST-elevation on an electrocardiogram (ECG) due to multiple etiologies including obstructive, non-obstructive, and/or angiographically normal coronary arteries. The incidence of ST-elevation myocardial infarction (STEMI) mimics in COVID-19 positive hospitalized patients, and the association with morbidity and mortality is unknown. Understanding the natural history and appropriate management of COVID-19 patients presenting with ST elevation is essential to inform patient management decisions and protect healthcare workers. Methods: The Society for Cardiovascular Angiography and Interventions (SCAI) and The Canadian Association of Interventional Cardiology (CAIC) in conjunction with the American College of Cardiology Interventional Council have collaborated to create a multi-center observational registry, North American COVID-19 ST-Segment Elevation Myocardial Infarction (NACMI). This registry will enroll confirmed COVID-19 patients and persons under investigation (PUI) with new ST-segment elevation or new onset left bundle branch block (LBBB) on the ECG with clinical suspicion of myocardial ischemia. We will compare demographics, clinical findings, outcomes and management of these patients with a historical control group of over 15,000 consecutive STEMI activation patients from the Midwest STEMI Consortium using propensity matching. The primary clinical outcome will be in- hospital major adverse cardiovascular events (MACE) defined as composite of all-cause mortality, stroke, recurrent MI, and repeat unplanned revascularization in COVID-19 confirmed or PUI. Secondary outcomes will include the following: reporting of etiologies of ST Elevation; cardiovascular mortality due to myocardial infarction, cardiac arrest and /or shock; individual components of the primary outcome; composite primary outcome at one year; as well as ECG and angiographic characteristics. Conclusion: The multicenter NACMI registry will collect data regarding ST elevation on ECG in COVID-19 patients to determine the etiology and associated clinical outcomes. The collaboration and speed with which this registry has been created, refined, and promoted serves as a template for future research endeavors.","Am Heart J","Dehghani, Payam","Davidson, Laura J","Grines, Cindy L","Nayak, Keshav","Saw, Jackie","Kaul, Prashant","Bagai, Akshay","Garberich, Ross","Schmidt, Christian","Ly Md Sm, Hung Q","Giri, Jay","Meraj, Perwaiz","Shah, Binita","Garcia, Santiago","Sharkey, Scott","Wood, David A","Welt, Frederick G","Mahmud, Ehtisham M","Henry, Timothy D","32425198"],"abstract":["Background: The novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), that causes coronavirus disease 2019 (COVID-19), has resulted in a global pandemic. Patients with cardiovascular risk factors or established cardiovascular disease are more likely to experience severe or critical COVID-19 illness and myocardial injury is a key extra-pulmonary manifestation. These patients frequently present with ST-elevation on an electrocardiogram (ECG) due to multiple etiologies including obstructive, non-obstructive, and/or angiographically normal coronary arteries. The incidence of ST-elevation myocardial infarction (STEMI) mimics in COVID-19 positive hospitalized patients, and the association with morbidity and mortality is unknown. Understanding the natural history and appropriate management of COVID-19 patients presenting with ST elevation is essential to inform patient management decisions and protect healthcare workers. Methods: The Society for Cardiovascular Angiography and Interventions (SCAI) and The Canadian Association of Interventional Cardiology (CAIC) in conjunction with the American College of Cardiology Interventional Council have collaborated to create a multi-center observational registry, North American COVID-19 ST-Segment Elevation Myocardial Infarction (NACMI). This registry will enroll confirmed COVID-19 patients and persons under investigation (PUI) with new ST-segment elevation or new onset left bundle branch block (LBBB) on the ECG with clinical suspicion of myocardial ischemia. We will compare demographics, clinical findings, outcomes and management of these patients with a historical control group of over 15,000 consecutive STEMI activation patients from the Midwest STEMI Consortium using propensity matching. The primary clinical outcome will be in- hospital major adverse cardiovascular events (MACE) defined as composite of all-cause mortality, stroke, recurrent MI, and repeat unplanned revascularization in COVID-19 confirmed or PUI. Secondary outcomes will include the following: reporting of etiologies of ST Elevation; cardiovascular mortality due to myocardial infarction, cardiac arrest and /or shock; individual components of the primary outcome; composite primary outcome at one year; as well as ECG and angiographic characteristics. Conclusion: The multicenter NACMI registry will collect data regarding ST elevation on ECG in COVID-19 patients to determine the etiology and associated clinical outcomes. The collaboration and speed with which this registry has been created, refined, and promoted serves as a template for future research endeavors."],"journal":"Am Heart J","authors":["Dehghani, Payam","Davidson, Laura J","Grines, Cindy L","Nayak, Keshav","Saw, Jackie","Kaul, Prashant","Bagai, Akshay","Garberich, Ross","Schmidt, Christian","Ly Md Sm, Hung Q","Giri, Jay","Meraj, Perwaiz","Shah, Binita","Garcia, Santiago","Sharkey, Scott","Wood, David A","Welt, Frederick G","Mahmud, Ehtisham M","Henry, Timothy D"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32425198","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.ahj.2020.05.006","locations":["North American","North American"],"topics":["Treatment"],"weight":1,"_version_":1667252837717901312,"score":330.7337},{"pmid":32478957,"title":"Adapting STEMI care for the COVID-19 pandemic: The case for low-risk STEMI triage and early discharge.","text":["Adapting STEMI care for the COVID-19 pandemic: The case for low-risk STEMI triage and early discharge.","The coronavirus pandemic has resulted in the need for rapid assessment of resource utilization within our hospital systems. Specifically, the overwhelming need for intensive care unit (ICU) beds within epicenters of the pandemic has created a need for consideration as to how acute coronary syndrome cases, and specifically ST-elevation myocardial infarction (STEMI) patients, are managed postprocedure. While most patients in the United States continue to be managed in coronary care units after primary percutaneous coronary intervention, there is a robust literature regarding the ability to triage STEMI patients safely and efficiently with low-risk features to non-ICU beds. We review the various risk scores for STEMI triage and the data supporting their usage. In summary, these findings support an approach to low-risk STEMI triage that does not come at the expense of quality patient care or outcomes, where up to two-thirds of patients with STEMI may be able to be safely managed without ICU-level care.","Catheter Cardiovasc Interv","Lopez, John J","Ebinger, Joseph E","Allen, Sorcha","Yildiz, Mehmet","Henry, Timothy D","32478957"],"abstract":["The coronavirus pandemic has resulted in the need for rapid assessment of resource utilization within our hospital systems. Specifically, the overwhelming need for intensive care unit (ICU) beds within epicenters of the pandemic has created a need for consideration as to how acute coronary syndrome cases, and specifically ST-elevation myocardial infarction (STEMI) patients, are managed postprocedure. While most patients in the United States continue to be managed in coronary care units after primary percutaneous coronary intervention, there is a robust literature regarding the ability to triage STEMI patients safely and efficiently with low-risk features to non-ICU beds. We review the various risk scores for STEMI triage and the data supporting their usage. In summary, these findings support an approach to low-risk STEMI triage that does not come at the expense of quality patient care or outcomes, where up to two-thirds of patients with STEMI may be able to be safely managed without ICU-level care."],"journal":"Catheter Cardiovasc Interv","authors":["Lopez, John J","Ebinger, Joseph E","Allen, Sorcha","Yildiz, Mehmet","Henry, Timothy D"],"date":"2020-06-02T11:00:00Z","year":2020,"_id":"32478957","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1002/ccd.28993","keywords":["pci","stemi","acute coronary syndrome","pandemic"],"locations":["United States"],"countries":["United States"],"countries_codes":["USA|United States"],"topics":["Prevention"],"weight":1,"_version_":1668437835163631616,"score":330.32434},{"pmid":32339038,"title":"STEMI Care and COVID-19: The Value Proposition of Pharmacoinvasive Therapy.","text":["STEMI Care and COVID-19: The Value Proposition of Pharmacoinvasive Therapy.","The coronavirus 2019 (COVID-19) pandemic has dramatically altered the delivery of reperfusion therapy for patients with ST-elevation myocardial infarction (STEMI). At this crucial time, it seems prudent to re-evaluate STEMI reperfusion pathways.","Circ Cardiovasc Qual Outcomes","Bainey, Kevin R","Bates, Eric R","Armstrong, Paul W","32339038"],"abstract":["The coronavirus 2019 (COVID-19) pandemic has dramatically altered the delivery of reperfusion therapy for patients with ST-elevation myocardial infarction (STEMI). At this crucial time, it seems prudent to re-evaluate STEMI reperfusion pathways."],"journal":"Circ Cardiovasc Qual Outcomes","authors":["Bainey, Kevin R","Bates, Eric R","Armstrong, Paul W"],"date":"2020-04-28T11:00:00Z","year":2020,"_id":"32339038","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1161/CIRCOUTCOMES.120.006834","keywords":["pharmacoinvasive therapy"],"topics":["Prevention"],"weight":1,"_version_":1666138494189174785,"score":307.94745}]}